MAIA Biotechnology Reports $8.9 Million Net Loss in Latest Quarter, Increases Investment in Clinical Trials

MAIA Biotechnology, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of $8.9 million for the third quarter, a 225% increase from the $2.7 million loss reported in the same period last year. For the nine months ending September 30, 2025, the net loss was approximately $18.8 million, a slight improvement compared to the $19.7 million loss for the same period in 2024. The increase in losses was primarily attributed to a substantial rise in operating expenses, which totaled $9.4 million for the quarter, up 123% from $4.2 million in the prior year.

Research and development expenses surged by 138% to $6.4 million in the third quarter, driven by increased clinical trial activities and related costs. General and administrative expenses also rose significantly, increasing by 97% to $3 million, largely due to higher professional fees and investor relations costs. The company’s total operating expenses for the nine months reached $20 million, an increase of 67% from the previous year, reflecting ongoing investments in its clinical programs.

In terms of operational metrics, MAIA Biotechnology has made strides in its clinical development efforts. The company is advancing its lead product candidate, ateganosine, through various clinical trials, including a pivotal Phase 2 trial for non-small cell lung cancer (NSCLC). The company has also expanded its geographic footprint, with ongoing trials in Australia and new patient enrollments in Taiwan and Turkey. As of September 30, 2025, MAIA had approximately $10.9 million in cash, an increase from $9.6 million at the end of 2024, but it reported a working capital deficit of approximately $1.8 million.

Strategically, MAIA has engaged in several financing activities, including private placements and an at-the-market offering, which collectively raised over $13 million in the first nine months of 2025. The company plans to continue raising capital to support its clinical trials and operational needs. Additionally, MAIA has adopted a Digital Asset Treasury Plan, allowing it to allocate a portion of its reserves to cryptocurrencies, which may impact its liquidity and capital resources in the future.

Looking ahead, MAIA Biotechnology anticipates continued investment in its clinical programs, with plans to initiate a Phase 3 trial for ateganosine in 2025. The company remains focused on securing additional funding to support its operations and clinical development, while navigating the challenges posed by its current financial position and the broader market conditions.